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During the past decade, medical science has paid consid-
erable attention to the use of human tissue and cells,
and their product modifications, in treating illness.
Medical devices making use of tissue and cells are now
used in supplementary procedures to conventional tissue
transplants and implants (allografts). Biotechnological
methods can be used to manufacture new, innovative
products from tissue and cells. This product group also
covers products containing the patient’s own cells.
Although the range of products on the market is still
limited, there is a lot of research and development activ-
ity in this field at present. For instance, demineralised
bone tissue for orthopaedic applications, and artificial
skin based on human cells for treating wounds are now
common in clinical use. Tissue engineering has made
vascular grafts and aortic valves possible. Combining
tissue engineering and cell therapy has resulted in func-
tional pancreatic tissue, etc. These are examples of
products soon to emerge from the R & D laboratories
to the market. 
Increased use of products of human origin, the con-
cern about their quality and safety, and the associated
ethical issues, have alerted the European Commission.
EU member states have been under heavy pressure to
harmonise the major issues. It has resulted in a Draft
Directive being issued in June 2002 about imposing
standards of quality and safety on the donation, pro-
curement, testing , processing , storage and distribution
of human tissue and cells (known as the human tissue
directive)1. It is proposed that blood and blood products
(apart from the stem cells of blood), and human organs,
should be excluded from the Draft Directive. Blood and
blood products are already regulated by two Directives2,3
and a recommendation by the Council4. In addition, the
so-called blood safety directive5 concerning blood trans-
fusion services is pending. The proposal is also likely to
exclude human tissue and cells removed and then im-
planted in the same patient. Cell therapy products are
currently controlled under the Medicinal Products Di-
rective2. 
Concurrently, the Commission has begun to draft a
directive on tissue engineering. An open consultation
process on an appropriate structure of the Directive is in
progress at present. The question is whether to apply
the marketing authorisation procedure of medicines, the
medical devices conformity assessment procedures, or
pick from these what is relevant for, and applicable to,
the product range in question. For the past ten years,
the industry has  urged for the creation of harmonised
European requirements. Now the Commission and the
authorities in member states are also feeling the need for
harmonised regulations in order to ensure patient safety.
A rosy future has been forecast for bioengineering
products. There are high expectations for the future of
new innovations. Competition between research teams
is fierce. The opportunity to prosper by trading in new
products seems attractive. In a recent technological re-
view on the medicines control of bioengineering R & D,
published by TEKES, The National Technology Agency
of Finland, it is claimed that capital would be available
for high risks investments, but knowledge about the re-
quirements imposed by the authorities is scant. 
The legislators must see to it that national legislation
provides for patient safety without loopholes. When
drafting Community legislation, one must look ahead,
recognise broad entities, and provide for the necessary
co-ordination. In Finland, legislation of this kind is
drafted by the Ministry of Social Affairs and Health.
The National Agency for Medicines assists the Ministry
with its expertise. The avalanche of bioengineering
products poses new challenges for the National Agency
for Medicines; its range of expertise needs to be extend-
ed and broadened.
1 COM/2002/0319 final*
2 2001/83/EC
3 2000/70/EC
4 98/463/EC
5 COM/2000/0816 final
*http://europa.eu.int/eur-lex/  
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Corticosteroids* are widely used an-
ti-inflammatory and immunosup-
pressive drugs. Their role is still im-
portant in the treatment, for in-
stance, of several skin diseases.
Problems in the use of cortico-
steroids are generally to be expected
when treatments become long-term
or when long-term treatments are
being withdrawn.
Reports of hydrocortisone-in-
duced allergy were received for the
first time in the 1950s (1). It was
nevertheless only admitted in the
1970s that contact allergy caused by
corticoids did occur, albeit uncom-
monly (2). The last two decades
have shown that contact allergy
caused by corticosteroids is definite-
ly more common than previously
thought. An estimated 1–2% of peo-
ple with persistent rash have been
sensitised to one or more corticos-
teroids (3). Present estimates of inci-
dences vary between 0.5% and 5%
(4).
Clinical picture of an allergic 
reaction
When an undeniable eczema is not
cured by a cortisone ointment, but,
in the worst scenario, symptoms are
exacerbated instead, the physician in
charge of treatment will start having
doubts about the diagnosis or the ef-
ficacy of the ointment, and the pa-
tient will lose his confidence in the
skills of his physician. The period of
illness may be prolonged, because
the patient who has become allergic
to a steroid is often suffering from a
long-term rash already as such, e.g.
eczema in situ, and the slowness of
cure does not come as a surprise.
The symptoms of corticosteroid-in-
duced contact allergy are seldom
dramatic, partly because the anti-in-
flammatory property of steroids
may mask the allergic reaction. Con-
sequently a mild corticoid may be
replaced with varying success by a
more potent one in the hope of im-
proved response to treatment.
If the corticoid responsible for
the contact allergy is administered to
the patient systemically, it may cause
the original rash areas to flare up
again or even lead to exanthema
and purpura (5-6). Contact allergy
to corticosteroids has been reported
also in patients who have used corti-
costeroids by inhalation or as a
nasal application, though only to a
small extent considering their wide-
spread use (7).
The skin areas typically display-
ing symptoms include the feet,
hands and face. The risk groups
may consist of patients suffering, for
instance, from atopic, allergic or
other persistent eczema and leg ul-
cers. 
Diagnosis presents several 
pitfalls
With an eczema patient responding
poorly to treatment, corticoid-in-
duced contact allergy should be sus-
pected early on. In Finland contact
allergies are studied with epicuta-
neous (patch) tests (8). Study of al-
lergies is nevertheless constantly un-
dergoing change. Discussion is
aroused, e.g., by issues relating to
the corticoid concentration and the
ointment in which it should be test-
ed (9). False positive and negative
reactions may also cause headaches.
The former reactions might at least
be provoked by response to the
medium, and the latter by the
above-mentioned anti-inflammatory
effect of the steroids, the physio-
chemical properties of the test sub-
stance, poor mixing with the oint-
ment, insufficient penetration of the
skin, inadequate concentration,
degradation of the corticoid during
storage, its vasoconstrictive property
(especially on the first test reading)
etc. (10). Test responses to steroids
anyway do not completely resemble
typical epicutaneous reactions. The
absorption of a corticosteroid oint-
ment by healthy skin tested on the
back is also poorer than by a skin
area which is being treated, and
consequently the reactions seen with
use of the ointment will not neces-
sarily be seen in a test situation.
What is tested and where?
As the proportion of incidences of
steroid-induced allergies among con-
tact allergies exceeded 1%, tixocor-
tol pivalate and budesonide have
been incorporated into the basic se-
ries of epicutaneous tests at the der-
matology units of the university hos-
pitals and the Institute of Occupa-
tional Health in Finland (8). Tixo-
cortol pivalate has been chosen to
represent hydrocortisone-induced re-
actions because it works better in
test situations and cross-reacts with
hydrocortisone. Tixocortol pivalate
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is tested as a 1.0% and budesonide
as a 0.1% ointment with petroleum
jelly. Most of the corticosteroid-in-
duced allergies are detected by hy-
drocortisone or tixocortol pivalate
and budesonide (11), and these are
recommended in Europe-wide stan-
dardised epicutaneous test series
(12). A late reading (6th–8th day) is
important: without it, as many as a
third of corticosteroid-induced con-
tact allergies will go undetected (13).
Individual, tailor-made arrange-
ments of the tests regarding the rele-
vant area and case according to the
prescribing practice of corticoster-
oids and the patient’s customary us-
age are recommended in cases diffi-
cult to solve (14). If the patient ex-
hibits an allergic reaction to tixocor-
tol pivalate or budesonide, a corti-
costeroid test series is nevertheless
recommended to be carried out, be-
cause a large number of patients be-
come allergic to several corticoids
while their long-term rash is being
treated with various preparations.
As the penetration of the steroid in
epicutaneous testing may be inade-
quate and the test result is about to
become falsely negative, an intracu-
taneous test is often also carried out,
which involves the injection of an
appropriately diluted substance into
the skin of the forearm followed by
a reading after 48 hours (15).
Testing of corticosteroid-induced
allergies is a finely tuned activity
which requires high expertise and
long-term experience and should
consequently be assigned to an espe-
cially dedicated allergy testing labo-
ratory or a specialist unit.
The test applied, ROAT (repeat-
ed open application test), is an easy-
to-use practical test method which
reflects the clinical response of the
corticoid used better than an epicu-
taneous test does. The ointment is
applied to the inside of the forearm
until a reaction is obtained or for a
maximum period of one week. A
large number of patients exhibiting
a reaction in the epicutaneous tests
will also react in the test analogous
to use, which can be used as a com-
plementary method (16).
Cross-reactions
Corticosteroids may cause cross-al-
lergy: patients were detected as hav-
ing allergic test reactions to steroids
to which they had never been ex-
posed. Clinical studies and studies
based on molecular structures have
resulted in categorisation in four dif-
ferent groups in accordance with
their allergenic properties (17).
Cross-reactions are much more com-
mon between corticoids with a
closely similar structure and of the
same group, than between those be-
longing to different structural
groups. The structure of budesonide
is special compared to that of other
corticoids, and reactions to it in an
epicutaneous test may indicate aller-
gy to corticoids even of two quite
different groups. It is suggested that
halogenated steroids would cause
fewer contact allergies than non-
halogenated ones, the likely reason
being that the amount of potent
halogenated steroid required is
smaller, in which case the amount of
antigens is also smaller and conse-
quently also the risk of developing
an allergy (18).
What follows after the tests? 
In the optimum cases the patient’s
poor healing tendency or exacerba-
tion of the rash will be clarified by
adequately extensive allergy tests.
There is a great likelihood that the
tests will either confirm or exclude a
contact allergy. The cause of the
problem is often a preservative con-
tained in the ointment or an antimi-
crobial ingredient or something sim-
ilar, and the corticoid proves to be
innocent. An appropriate therapy
should be found for the patient after
testing in order to control the origi-
nal skin problem. Thorough patient
guidelines are important; these
should contain in addition written
information about inappropriate
(and cross-reacting) corticosteroids
as well as appropriate ones. A list of
trade names of all synonymous
preparations available on the market
will be of tremendous benefit for the
patient’s subsequent self-treatment.
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Statins are HMG-CoA-reductase in-
hibitors with an inhibiting effect on
cholesterol synthesis by the liver
cells and an accelerating effect on
LDL-receptor synthesis, causing a
reduction in the plasma LDL-choles-
terol concentration. 
Clinical studies have shown mild
elevations of serum creatine kinase
(S-CK) at most in a couple of per-
cent of healthy volunteers. 
Once statins became more widely
used, myopathies were occasionally
found to occur in patients during
treatment. Symptoms may be mani-
fested as muscular pain, tenderness
or weakness, not necessarily associ-
ated with an increased creatine ki-
nase (CK) level, or myositis. In
rhabdomyolysis, the muscular symp-
toms are severe, the CK level is over
10 times higher than the maximum
baseline level, and the rising serum
creatinine level is a sign of impaired
renal function. Rhabdomyolysis may
become life-threatening, especially if
associated with renal necrosis. 
The first statin was introduced
on to the Finnish market in 1988.
According to the drug reimburse-
ment statistics of the Social Insur-
ance Institution, a total of 260,000
patients obtained refunds for statins
last year. The wholesale consump-
tion of statins is shown in Figure 1.
Until the end of 2001, estimated 
cumulative exposure to lovastatin is
182,000 patient years, to simvasta-
tin 282,000, to fluvastatin 73,000,
to pravastatin 49,000, to atorvasta-
tin 168,000, and to cerivastatin
3,000 patient-years.
Statin-associated reports
Since 1988 up until the end of Au-
gust 2002, the National ADR Regis-
ter received in total 242 reports of
adverse reactions of statins (Fig. 2).
A total of 106 muscular reac-
tions were reported in 79 patients.
Any one patient may have exhibited
more than one symptom. The esti-
mated reporting frequency of statin-
associated ADRs has been about
1:8,000 and of myopathies 1:19,000
recipients. 
Rhabdomyolysis
Rhabdomyolysis was reported in
eight cases (Table 1). A half of these
patients needed intensive care treat-
ment. All patients were recovered. 
Most patients had contributing
disorders and drug treatments. The
dose of simvastatin had been dou-
bled in three patients before mani-
festation of rhabdomyolysis. In a pa-
tient administering long-term lovas-
tatin rhabdomyolysis appeared in
two weeks from the start of itra-
conazole therapy. 
Other muscle reactions
The ADR Register had during the
above period received 32 repåorts on 
neurological adverse reactions
which included two cases of
sensorymotor polyneuropathy in pa-
tients on atorvastatin therapy, diag-
nosed and verified by an electroneu-
romyographical examination. In one
case the symptoms and signs were di-
rected towards the lower limbs and
were mild and reversible; in the other
they were directed towards the upper
limbs, were severe, and were respon-
sible for permanent muscular atrophy
and impaired function of the hands. 
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Figure 1. Consumption of statins in Finland 1990–2001
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Table 1 .  Stat in-associated rhabdomyolysis  in  F inland 1988–31.8.2002
Year Statin and daily dose Interactive drug Age and sex of patient
2001 Simvastatin 40 mg None 68-year-old female
2002 Simvastatin 80 mg* Macrolide 50-year-old male
2001 Simvastatin 80 mg* Gemfibrozil 55-year-old female
2000 Simvastatin 80 mg* Ciclosporin 52-year-old male
2001 Simvastatin 80 mg Fluvoxamine 51-year-old female
1996 Lovastatin 80 mg Itraconazole 54-year-old female
1998 Pravastatin 20 mg Bezafibrate 66-year-old female
2001 Cerivastatin 300 microg None 54-year-old male
* The dose had been doubled 
Factors predisposing to myopathy
Well-known risk factors for  statin-
associated adverse muscular reac-
tions include high doses of statins,
advanced age, chronic renal failure,
other muscular disease, multi-drug
therapy and the postoperative state.
The lipophilic property of statins is
under discussion. The safety of use
of different statins has not been
studied in this context. The differ-
ences in statin-associated myotoxici-
ty can in several cases be explained
by varying drug-metabolising liver
enzymes, cytochrome-P450. The me-
tabolism of simvastatin, atorvastatin
and lovastatin is mainly mediated by
CYP3A4. The clinically important
inhibitors of CYP3A4-mediated me-
tabolism include, among others, cy-
closporin, itraconazole, ketocona-
zole, diltiazem, verapamil, nifedip-
ine, erythromycin, clarithromycin, 
and several anti-HIV drugs.
As a result of such interaction, the
clearance of the above statin may be
reduced and its plasma concentra-
tion may reach toxic levels. Abun-
dant intake of grapefruit juice and
alcohol may cause a similar harmful
interaction.  Many CYP3A4 inhibi-
tors also are substrates or inhibitors
of P-glycoprotein which may con-
tribute to interaction. Fluvastatin
metabolism is mediated by CYP2C9.
CYP system does not mediate
pravastatin metabolism. 
The risk of myopathy increases
also with concurrent use of fibrates
with statins. 
Conclusions
In general, myotoxicity is a rare ad-
verse reaction. The life-threatening
rhabdomyolysis is most probably a
very rare and dose-dependent class
effect of statins, in which also inter-
actions may play a big role.
In order to avoid the statin-asso-
ciated adverse effects, individual
dosage should carefully be consid-
ered, and the risk of interactions be-
tween drugs should be noticed. 
When interpreting this data care-
ful consideration is recommended
because the present material of
ADRs has been obtained by the reg-
ulatory authority as spontaneous re-
ports from physicians. The data can
not be used for comparison of safety
of various statins.
The EU CPMP Pharmacovigi lance Working Party recommends the mea-
suring of  S-CK prior  to commencement of  stat in therapy in the fol low-
ing cases where the patient  is  increasingly exposed to rhabdomyolysis
• Renal impairment
• Hypothyroidism
• Personal or familial history of hereditary muscular disorders
• Previous history of either statin or fibrate-induced muscular toxicity 
• Alcohol abuse
• In elderly ( age > 70 years), the necessity of such measurement should be consid-
ered, according to the presence of other predisposing factors for rhabdomyolysis.  
In these cases, the risks involved should always be weighed against the benefit of
the treatment, and the patient's clinical status should be closely monitored. 
If on checking the S-CK baseline level exceeds the five-fold maximum reference
value, the introduction of statin therapy is not recommended.
Whilst  on treatment
The S-CK level should always be measured if myalgia, weakness or muscle cramps
occur during treatment. Should the S-CK level exceed the five-fold maximum refer-
ence value, statin therapy should be discontinued. If the muscular symptoms are
clinically severe, statin therapy should be discontinued despite only slightly elevated
S-CK levels.
If the muscular symptoms disappear and the S-CK level returns to normal, it may
after some time be considered, at the lowest possible dose and with close monitor-
ing of the patient.
Figure 2. Statin-associated adverse reactions in Finland 1988–31.8.2002
s.32-39  13.10.2002  16:03  Page 36
TABU 5.2002 37
Information on prescription drugs is
obtained by medical doctors in the
form of pharmaceutical presenta-
tions and as mail sent to their home
addresses, but the vast majority of it
comes as advertisements published
in the professional journals. The
doctor’s first source of information
about a newly introduced drug is of-
ten a pharmaceutical advertisement.
The marketing of pharmaceuti-
cals in Finland is supervised by the
National Agency for Medicines.
Pharma Industry Finland (PIF) also
supplies guidelines for pharmaceuti-
cal marketing (1), which the mem-
ber organisations have agreed to fol-
low. 
According to a regulation “mar-
keting material targeted at health
care personnel should, for instance,
always contain the essential details
which in accordance with the sum-
mary of product characteristics
(SPC) are related to the indications
and recommendations for use of the
preparation, including its efficacy
and safety of use” (2). The material
should also indicate the date on
which the leaflet was drawn up or
renewed. According to the guide-
lines for pharmaceutical marketing,
the marketing of drugs targeted at
health care personnel must be up-to-
date and in accordance with the SPC
concerned and should contain all
relevant information necessary for
the prescription of the drug.  The
details given concerning the drug
should also be clear and easy to un-
derstand (1).
Considering the above regula-
tions and guidelines and the fact
that about one in every ten medical
doctors in  primary health care relies
on the advertisements in profession-
al journals as a source of informa-
tion, one would think that drug ad-
vertisements were unambiguous and
complete information packets as far
as their contents are concerned.
This review was aimed at finding
out whether this would be the case:
what information do the advertise-
ments reveal and how well does it
comply with the information given
in the SPCs?
Material and methods
The material used consisted of phar-
maceutical advertisements in the
medical journals, Lääketieteellinen
Aikakauskirja Duodecim and the
Finnish Medical Journal (Suomen
Lääkärilehti), issues of April and
May 2002.  The total number of is-
sues of the journals was 12, out of
which 8 were of the Finnish Medical
Journal.  The advertisements num-
bered 94 in all. The majority of
these (87) were advertisements of
prescription only medicines. Some of
these (7 in all) were advertisements
of  drugs which were available with-
out prescription in their smallest
package format, while  the larger
formats were only available on pre-
scription.
Seven of the advertisements were
divided into two, so that a section of
them, the text relating to the SPC,
was to be found elsewhere in the
journal.  Four of these advertise-
ments referred to the fact that infor-
mation on the SPC would be else-
where in the journal, and one of
them included the page number.  In
three cases the continuation of the
advertisement was not referred to at
all, and so they were interpreted in-
dividually as separate advertise-
ments.
Several advertisements included
different forms and potencies for the
same drug.  They have in this review
been treated as one advertisement.
Advertisements of OTC drugs and
reminders of advertisements were
excluded from the review.  Accord-
ing to a regulation of the National
Agency for Medicines, a reminder of
an advertisement may only refer to
the name of the drug, or the name
and the marketing authorisation
holder (2).
The advertising texts were com-
pared with the texts of the SPCs.
The following items were compared:
the medicinal substance/substances,
indications, contraindications, inter-
actions, adverse effects, special
warnings and use during pregnancy
and lactation. Whether these items
had been referred to in the adver-
tisements was checked, and if they
had been, to what extent.  Whether
the advertisement contained the date
(month and year) of the preparation
of  the material or the date of the
latest renewal was also checked. A
closer examination was carried out
on advertisements with discrepancies
in the above information. Details on
packaging, price and references were
not studied in this review.
Results
The number of companies advertis-
ing their products was 28. Not a
single advertisement stated that the
drug was safe to use or that it did
not have adverse effects or that its
use was not associated with a risk of
Pharmaceutical advertising in professional
journals for medical doctors
Satu Saarinen
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Drug Information Centre
National Agency for Medicines
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dependency.  The name of the drug
was missing in three advertisements
(Table 1).  One of them mentioned
the relevant group of medicinal sub-
stances but did not reveal the name
of the drug. In two other advertise-
ments the name of the active sub-
stance was indirectly obvious from
the name of the preparation, but
was not explicitly mentioned.  Fur-
thermore, the name of the medicinal
substance in one advertisement was
visible only on the picture of the
drug package.
Indications
The wording on the factual contents
and on the indications in most of
the advertisements in the review
were the same as in the relevant
SPCs.  Seven advertisements had
definite defects or mistakes in the
reference to the indications (Table
2).  In two of these advertisements
the indications for children and
adults were different, but this was
not disclosed.  In three advertise-
ments the references to the indica-
tions were  excessively general: more
accurate information (e.g. for whom
and in what circumstances  the drug
would be indicated) was absent.
Essential information relating to
administration was missing in two
advertisements.  In one of the adver-
tisements (for an antibiotic) a whole
range of infections were referred to
as indications without stating any
restrictions for use.  In the other ad-
vertisement with definite discrepan-
cies in the content of information,
the indications were not stated clear-
ly; instead, the advertisement em-
phasised the degree of prophylactic
effect the drug had against  certain
diseases.
Contraindications
All  the SPCs referred to some con-
traindications.  In about 86% of the
advertisements all the contraindica-
tions were listed.  Only the most
common ones were mentioned in
14% of the advertisements (Table
1).  References to  contraindications
were missing altogether in about 4%
of the advertisements (Table 2).  As
a matter of fact, three of these SPCs
mentioned only hypersensitivity as a
contraindication, and consequently
only one advertisement lacked actu-
al reference to contraindications.
Interactions
The SPCs of seven drugs did not
mention a single interaction. The
most general interactions were men-
tioned in about a fifth of all the ad-
vertisements, and all of the interac-
tions in about a third of them (Table
1).
References to  interactions were
missing altogether in about a half of
the advertisements.  According to
nearly all of these SPCs, interactions
were clinically possible, and conse-
quently, the most common or most
important ones should have been
mentioned in the advertising materi-
al.
Adverse effects
Nine of the advertisements detailed
all the adverse reactions mentioned
in the SPCs.  Over a half of the ad-
vertisements detailed the most com-
mon adverse effects (Table 1), and a
third of these also mentioned some
rarer adverse effects.
No adverse reactions at all were
mentioned in 19% of the advertise-
ments even though the SPCs of all of
these drugs did describe some (Table
2). In addition, no adverse effects
were disclosed in one advert, but, it
being for an insulin, the borderline
between adverse effects and warn-
ings is very difficult to determine.
Among the advertisements without
any mention of adverse effects, five
had covered them with a general
comment such as “adverse effects
are similar to those caused by a
placebo”, or “adverse effects are
generally mild”. One advertisement
referred to general adverse effects
found in similar drugs: “the adverse
reactions reported were usually re-
lated to the pharmacological effects
of beta-blockers”. The SPCs of all
these drugs described adverse effects
which, according to regulations,
should have been disclosed in the
advertising material.
The style of the advertisements
lacking information on adverse ef-
fects was conspicuous without being
particularly informative.  One ad-
vertisement, for instance, described
how well the risks of various dis-
eases were prevented by the drug,
but without conveying the informa-
tion contained in the SPC.
Special warnings
Over a half of the advertisements
listed special warnings (Table 1).
One of the drug advertisements stat-
ed that the warnings could be
looked up in the Pharmaca Fennica.
All the drugs with no mention of
special warnings in their advertising
listed some warnings in their SPCs.
Nearly all of these warnings were
associated with adverse effects or
diseases in connection with which
the drug should be used. About a
half of these also contained instruc-
tions or advice on the monitoring of
Table 1 .   The number and proport ion of  the i tems mentioned in the SPCs (SPC) and advert isements (A);  al l
or  the most  common ones are mentioned
all most common
mentioned ones mentioned
Items mentioned n SPC/SPC (%) n A/SPC (%) (%) (%)
The medicinal substance 94 100 91 97
Indications 94 100 94 100 93 7
Contraindications 94 100 90 96 86 14
Interactions 86 91 49 57 41 59
Adverse reactions 93 99 76 82 12 88
Special warnings 93 99 57 61
Pregnancy and lactation 87 93 43 49
Date 5 5
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the patient’s condition or of labora-
tory values.
Use during pregnancy and lactation
Use during pregnancy and lactation
had been mentioned in about half
the advertisements (Table 1). In all
of these cases, according to the SPC,
the drug is either contraindicated
during pregnancy or lactation, or
should only be used if absolutely
necessary, or the use of the drug had
not been studied, and so it was ad-
vised that it should not be used.
Among the advertisements with no
mention of pregnancy or lactation,
six stated in their SPCs that there
were no obstacles to using the drug
under such conditions, or that the
issue was irrelevant (e.g. in relation
to drugs for treating prostatic dis-
ease).
Date
Only five percent of the advertise-
ments clearly stated the date when
they were drawn up or their details
reviewed (Table 1).  In about 40%
of them the date was placed on the
margin of the advertisement either
as such or as part of a code. 57% of
the advertisements lacked a date al-
together.
Conclusions
In general, nearly all essential infor-
mation with regard to the correct
and safe use of the drug was well
detailed.  The text containing the
drug information was nevertheless
given in small print in nearly all of
the advertisements, and was very
difficult to read.  It gave the impres-
sion that the texts were intended for
reading by young people only and in
excellent light.  The picture often
covered most of the advertising
space, which raises the inevitable
question about the purpose: is it the
impression produced by the adver-
tisement or the information con-
tained in it?
Those advertisements where the
text of the SPC was to be found
elsewhere in the journal were mis-
leading, especially if there was no
connection between the two parts of
the advertisement. In such cases it
would be easy for the reader only to
notice the larger and more conspicu-
ous part of the advertisement, in
which case the information received
from the advertisement will remain
incomplete or be lacking altogether.
About a half of the advertise-
ments did not include any warnings
whatsoever, and about 19% of them
did not list any adverse effects at all
(Table 2). It is very difficult to assess
which of the warnings or mentions
of adverse effects are essential and
ought therefore to be included in the
advertising. Should, for instance,
rare adverse effects be included, and
if so, should all of them be men-
tioned? If only some were selected,
on what basis should it be done?
The situation has fortunately im-
proved considerably since 1998. Ac-
cording to a review done at the
time, adverse effects were missing in
89%, contraindications in 73% and
special warnings in 86% of the ad-
vertisements (3). According to a
Finnish review done in 2000, for in-
stance, adverse effects were no
longer missing in more than only a
half of the adverts. There has been
no change in the situation for the
last two years, however: similar im-
portant information is still missing.
As Paul stated in his review, it is un-
likely that the absence of safety data
will cause any major adverse effects,
because physicians will hardly pre-
scribe drugs to their patients based
on drug advertisements alone.
It is required by the regulation
on pharmaceutical advertising that
the information on the drug ob-
tained by the reader of the advertise-
ment should be adequate for form-
ing an opinion on its therapeutic ef-
fect (2).  Based on the perception of
this review, it cannot be concluded
that this requirement is fulfilled
completely.  Even though the major-
ity of readers will scan the advertise-
ments quickly, the importance of ad-
vertising as a source of information
should not be undervalued. Correct-
ly used, pharmaceutical advertising
is an excellent channel for providing
circumstantial information on drugs
for the prescribing physician.
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